NDA 019627 · Fresenius Kabi USA
Diprivan
Propofol · Injection · General Anesthetic
NovelLast checked: Nov 20, 2026Latest source record: Nov 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Oct 2, 1989
Approved uses
5
Original approval plus efficacy supplements
Registered trials
1,886
195 Phase 3, 129 recruiting
FAERS reports
37,021
34,684 serious, 5,006 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 11, 2025.
DIPRIVAN is an intravenous general anesthetic and sedation drug indicated for: • Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age • Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age • Initiation and Maintenance of Monitored Anesthesia Care (MAC) Sedation in Adult Patients • Sedation for Adult Patients in Combination with Regional Anesthesia • Intensive Care Unit (ICU) Sedation of Intubated, Mechanically Ventilated Adult Patients Limitations of Use DIPRIVAN is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations [see Pediatric Use ( 8.4 )] . Safety, effectiveness and dosing guidelines for DIPRIVAN have not been established for MAC sedation in the pediatric population; therefore, it is not recommended for this use [see Pediatric Use ( 8.4 )]. DIPRIVAN is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established [see Pediatric Use ( 8.4 )]. DIPRIVAN is an intravenous general anesthetic and sedation drug indicated for: • Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age • Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age • Initiation and Maintenance of Monitored Anesthesia Care (MAC) Sedation in Adult Patients • Sedation for Adult Patients in Combination with Regional Anesthesia • Intensive Care Unit (ICU) Sedation of Intubated, Mechanically Ventilated Adult Patients Limitations of Use : DIPRIVAN is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months....
Mechanism: The mechanism of action, like all general anesthetics, is poorly understood. However, propofol is thought to produce its sedative/anesthetic effects by the positive modulation of the inhibitory function of the neurotransmitter GABA through the ligand-gated GABA A receptors.
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 23, 2001 Supplement 35 · Efficacy LabelLetterReview
- Oct 26, 1993 Supplement 17 · Efficacy
- Mar 8, 1993 Supplement 10 · Efficacy
- Dec 31, 1991 Supplement 2 · Efficacy Review
- Oct 2, 1989 Original approval · Type 1 - New Molecular Entity Other Important Information from FDA
2 products under this application
- DIPRIVAN · PROPOFOL 10MG/ML · INJECTABLE, INJECTION · Discontinued
- DIPRIVAN · PROPOFOL 10MG/ML · INJECTABLE, INJECTION · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Propofol" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Long-term Outcome of General Anesthesia on DysgnosiaPivotal-lookingStatus unknown
Nanjing Medical UniversityAcademic, hospital or other
NCT01184638 · 10,000 participants (planned) · Start Aug 2010 · Primary completion Aug 2020
Drug: Sevoflurane; Propofol · For: Delirium,; Dementia,; Amnestic, and 1 more
Sites: Nanjing, China
- REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEryPivotal-lookingRecruiting
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
NCT05728775 · 7,188 participants (planned) · Start Apr 3, 2023 · Primary completion Dec 31, 2027
Drug: Remimazolam; Propofol · For: Anesthesia; Surgery-Complications
Sites: Hefei, China; Huainan, China; Suzhou, China · 44 sites in all
- The GUARDIAN Trial - Induction Agent Sub-StudyPivotal-lookingEnrolling by invitation
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT04934683 · 6,254 participants (planned) · Start Jul 25, 2021 · Primary completion Dec 31, 2026
Drug: Etomidate Induction; Propofol Induction · For: Major Surgery
Sites: Omaha, Nebraska; Cleveland, Ohio; Shanghai, China · 11 sites in all
- Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane AnesthesiaPivotal-lookingCompleted
Uppsala UniversityAcademic, hospital or other
NCT01975064 · 5,774 participants · Start Nov 2013 · Primary completion Aug 31, 2022
Drug: Propofol; Sevoflurane · For: Breast Neoplasms; Colonic Neoplasms; Rectal Neoplasms
Sites: Beijing, China; Shanghai, China; Xijing, China · 15 sites in all
- Anesthesia and Non-small Cell Lung Cancer RecurrencePivotal-lookingRecruiting
Samsung Medical CenterAcademic, hospital or other
NCT06330038 · 5,384 participants (planned) · Start Aug 5, 2024 · Primary completion Dec 31, 2028
Drug: Propofol; Inhaled anesthetics · For: Non-small Cell Lung Cancer; Surgery; Anesthesia
Sites: Seoul, South Korea
- Desflurane vs. Propofol for Cardiac AnesthesiaPivotal-lookingRecruiting
Xijing HospitalAcademic, hospital or other
NCT07116733 · 3,560 participants (planned) · Start Oct 20, 2025 · Primary completion Dec 31, 2028
Drug: Desflurane group; Propofol group · For: Cardiac Surgery; Coronary Artery Bypass Grafting
Sites: Fuzhou, China; Cangzhou, China; Shijiazhuang, China · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypotension2,992
- drug ineffective2,858
- anaphylactic shock2,182
- cardiac arrest1,851
- anaphylactic reaction1,762
- off label use1,736
- drug interaction1,583
- tachycardia1,234
- bradycardia1,212
- acute kidney injury1,024
- pyrexia1,024
- rhabdomyolysis932
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 583 |
| 2005 | 674 |
| 2006 | 630 |
| 2007 | 790 |
| 2008 | 798 |
| 2009 | 1,132 |
| 2010 | 976 |
| 2011 | 1,396 |
| 2012 | 1,186 |
| 2013 | 1,248 |
| 2014 | 1,148 |
| 2015 | 1,307 |
| 2016 | 1,622 |
| 2017 | 1,594 |
| 2018 | 2,060 |
| 2019 | 2,181 |
| 2020 | 2,738 |
| 2021 | 2,490 |
| 2022 | 2,361 |
| 2023 | 2,779 |
| 2024 | 2,477 |
| 2025 | 2,894 |
| 2026 | 1,944 |
Recalls
2 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Diprivan* (Propofol*) · HCPCS J2704
2024 spending
$113K
Beneficiaries
30,945
41,328 claims
Per beneficiary
$4
2024 ASP limit $0.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $106,991 |
| 2021 | $144,819 |
| 2022 | $137,330 |
| 2023 | $133,488 |
| 2024 | $113,209 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Remimazolam versus propofol for sedation in gastrointestinal endoscopic procedures: a systematic review and meta-analysis.
Barbosa EC, Espírito Santo PA, Baraldo S, et al. · Br J Anaesth 2024 · Comparative Study, Meta-Analysis
- Comparison of Fentanyl, Remifentanil, Sufentanil and Alfentanil in Combination with Propofol for General Anesthesia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Sridharan K, Sivaramakrishnan G · Curr Clin Pharmacol 2019 · Comparative Study, Meta-Analysis
- Efficacy and safety of Ciprofol compared with Propofol during general anesthesia induction: A systematic review and meta-analysis of randomized controlled trials (RCT).
Akhtar SMM, Fareed A, Ali M, et al. · J Clin Anesth 2024 · Meta-Analysis, Systematic Review
- Outcomes of dexmedetomidine versus propofol sedation in critically ill adults requiring mechanical ventilation: a systematic review and meta-analysis of randomised controlled trials.
Heybati K, Zhou F, Ali S, et al. · Br J Anaesth 2022 · Meta-Analysis, Systematic Review
- Anesthetic efficacy with remimazolam compared with propofol: a systematic review and meta-analysis of randomized controlled trials.
Xing Y, Lang Z, Wang X, et al. · Int J Surg 2025 · Systematic Review, Meta-Analysis
- A systematic review and meta-analysis of propofol versus midazolam sedation in adult intensive care (ICU) patients.
Garcia R, Salluh JIF, Andrade TR, et al. · J Crit Care 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.